These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

481 related items for PubMed ID: 31884801

  • 41. Suppressing the secretion of exosomal miR-19b by gw4869 could regulate oxaliplatin sensitivity in colorectal cancer.
    Gu YY, Yu J, Zhang JF, Wang C.
    Neoplasma; 2019 Jan 15; 66(1):39-45. PubMed ID: 30509090
    [Abstract] [Full Text] [Related]

  • 42. Prostaglandin F2α synthase promotes oxaliplatin resistance in colorectal cancer through prostaglandin F2α-dependent and F2α-independent mechanism.
    Wang YJ, Xie XL, Liu HQ, Tian H, Jiang XY, Zhang JN, Chen SX, Liu T, Wang SL, Zhou X, Jin XX, Liu SM, Jiang HQ.
    World J Gastroenterol; 2023 Oct 21; 29(39):5452-5470. PubMed ID: 37900995
    [Abstract] [Full Text] [Related]

  • 43. miR-139-5p sensitizes colorectal cancer cells to 5-fluorouracil by targeting NOTCH-1.
    Liu H, Yin Y, Hu Y, Feng Y, Bian Z, Yao S, Li M, You Q, Huang Z.
    Pathol Res Pract; 2016 Jul 21; 212(7):643-9. PubMed ID: 27173050
    [Abstract] [Full Text] [Related]

  • 44. Annexin A3 depletion overcomes resistance to oxaliplatin in colorectal cancer via the MAPK signaling pathway.
    Xu R, Yin J, Zhang Y, Zhang S.
    J Cell Biochem; 2019 Sep 21; 120(9):14585-14593. PubMed ID: 30998268
    [Abstract] [Full Text] [Related]

  • 45. The c-MYC-WDR43 signalling axis promotes chemoresistance and tumour growth in colorectal cancer by inhibiting p53 activity.
    Di Y, Jing X, Hu K, Wen X, Ye L, Zhang X, Qin J, Ye J, Lin R, Wang Z, He W.
    Drug Resist Updat; 2023 Jan 21; 66():100909. PubMed ID: 36525936
    [Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51. Cyclophilin B induces chemoresistance by degrading wild-type p53 via interaction with MDM2 in colorectal cancer.
    Choi TG, Nguyen MN, Kim J, Jo YH, Jang M, Nguyen NNY, Yun HR, Choe W, Kang I, Ha J, Tang DG, Kim SS.
    J Pathol; 2018 Sep 21; 246(1):115-126. PubMed ID: 29876924
    [Abstract] [Full Text] [Related]

  • 52. Mir-488 alleviates chemoresistance and glycolysis of colorectal cancer by targeting PFKFB3.
    Deng X, Li D, Ke X, Wang Q, Yan S, Xue Y, Wang Q, Zheng H.
    J Clin Lab Anal; 2021 Jan 21; 35(1):e23578. PubMed ID: 32990355
    [Abstract] [Full Text] [Related]

  • 53. Elevating H3K27me3 level sensitizes colorectal cancer to oxaliplatin.
    Wang Q, Chen X, Jiang Y, Liu S, Liu H, Sun X, Zhang H, Liu Z, Tao Y, Li C, Hu Y, Liu D, Ye D, Liu Y, Wang M, Zhang X.
    J Mol Cell Biol; 2020 Feb 20; 12(2):125-137. PubMed ID: 31065671
    [Abstract] [Full Text] [Related]

  • 54. Exploiting a novel miR-519c-HuR-ABCG2 regulatory pathway to overcome chemoresistance in colorectal cancer.
    To KK, Leung WW, Ng SS.
    Exp Cell Res; 2015 Nov 01; 338(2):222-31. PubMed ID: 26386386
    [Abstract] [Full Text] [Related]

  • 55. RNA-binding protein CELF1 enhances cell migration, invasion, and chemoresistance by targeting ETS2 in colorectal cancer.
    Wang H, Huang R, Guo W, Qin X, Yang Z, Yuan Z, Wei Y, Mo C, Zeng Z, Luo J, Cai J, Wang H.
    Clin Sci (Lond); 2020 Jul 31; 134(14):1973-1990. PubMed ID: 32677671
    [Abstract] [Full Text] [Related]

  • 56. The lncRNA CRNDE promotes colorectal cancer cell proliferation and chemoresistance via miR-181a-5p-mediated regulation of Wnt/β-catenin signaling.
    Han P, Li JW, Zhang BM, Lv JC, Li YM, Gu XY, Yu ZW, Jia YH, Bai XF, Li L, Liu YL, Cui BB.
    Mol Cancer; 2017 Jan 13; 16(1):9. PubMed ID: 28086904
    [Abstract] [Full Text] [Related]

  • 57. miR-625-3p regulates oxaliplatin resistance by targeting MAP2K6-p38 signalling in human colorectal adenocarcinoma cells.
    Rasmussen MH, Lyskjær I, Jersie-Christensen RR, Tarpgaard LS, Primdal-Bengtson B, Nielsen MM, Pedersen JS, Hansen TP, Hansen F, Olsen JV, Pfeiffer P, Ørntoft TF, Andersen CL.
    Nat Commun; 2016 Aug 16; 7():12436. PubMed ID: 27526785
    [Abstract] [Full Text] [Related]

  • 58. miR-19b-3p promotes colon cancer proliferation and oxaliplatin-based chemoresistance by targeting SMAD4: validation by bioinformatics and experimental analyses.
    Jiang T, Ye L, Han Z, Liu Y, Yang Y, Peng Z, Fan J.
    J Exp Clin Cancer Res; 2017 Sep 22; 36(1):131. PubMed ID: 28938919
    [Abstract] [Full Text] [Related]

  • 59. A panel of serum exosomal microRNAs as predictive markers for chemoresistance in advanced colorectal cancer.
    Jin G, Liu Y, Zhang J, Bian Z, Yao S, Fei B, Zhou L, Yin Y, Huang Z.
    Cancer Chemother Pharmacol; 2019 Aug 22; 84(2):315-325. PubMed ID: 31089750
    [Abstract] [Full Text] [Related]

  • 60. MiR-505 mediates methotrexate resistance in colorectal cancer by targeting RASSF8.
    Chen Y, Bian L, Zhang Y.
    J Pharm Pharmacol; 2018 Jul 22; 70(7):937-951. PubMed ID: 29726011
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 25.